E
Alterity Therapeutics Limited
PRNAF
$0.0101
$0.0065180.56%
E
Sell
2/28/2025Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 2/28/2025 due to a decline in the volatility index.
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 2/28/2025 due to a decline in the volatility index.
D
Sell
2/12/2025Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 2/12/2025 due to an increase in the total return index, volatility index and growth index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 2/12/2025 due to an increase in the total return index, volatility index and growth index.
E
Sell
1/23/2025Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 1/23/2025 due to a significant decline in the valuation index.
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 1/23/2025 due to a significant decline in the valuation index.
D
Sell
11/5/2024Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 11/5/2024 due to a decline in the volatility index, total return index and growth index.
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 11/5/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
10/21/2024Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 10/21/2024 due to a noticeable increase in the total return index and volatility index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 10/21/2024 due to a noticeable increase in the total return index and volatility index.
D
Sell
6/3/2024Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.0009 to -$0.0008, operating cash flow increased 0.48% from -$1.47M to -$1.46M, and EBIT increased 0.48% from -$2.17M to -$2.16M.
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.0009 to -$0.0008, operating cash flow increased 0.48% from -$1.47M to -$1.46M, and EBIT increased 0.48% from -$2.17M to -$2.16M.
E
Sell
10/26/2023Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 10/26/2023 due to a noticeable decline in the total return index and volatility index.
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 10/26/2023 due to a noticeable decline in the total return index and volatility index.
D
Sell
10/11/2023Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 10/11/2023 due to an increase in the volatility index and total return index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 10/11/2023 due to an increase in the volatility index and total return index.
E
Sell
9/26/2023Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 9/26/2023 due to a decline in the volatility index.
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 9/26/2023 due to a decline in the volatility index.
D
Sell
9/6/2023Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 9/6/2023 due to an increase in the volatility index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 9/6/2023 due to an increase in the volatility index.
E
Sell
8/25/2023Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 8/25/2023 due to a decline in the volatility index.
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 8/25/2023 due to a decline in the volatility index.
D
Sell
8/8/2023Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 8/8/2023 due to a substantial increase in the valuation index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D- from E+ on 8/8/2023 due to a substantial increase in the valuation index.
E
Sell
7/24/2023Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 7/24/2023 due to a decline in the volatility index, growth index and valuation index.
Alterity Therapeutics Limited (PRNAF) was downgraded to E+ from D- on 7/24/2023 due to a decline in the volatility index, growth index and valuation index.
D
Sell
3/14/2023Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and solvency index. Total revenue declined 3.84% from $815.8 to $784.5.
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and solvency index. Total revenue declined 3.84% from $815.8 to $784.5.
D
Sell
2/23/2023Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index and total return index.
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index and total return index.
D
Sell
5/16/2022Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 05/16/2022.
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 05/16/2022.
D
Sell
5/1/2022Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D+ on 5/1/2022 due to a large decline in the total return index and volatility index.
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D+ on 5/1/2022 due to a large decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D+ from D- on 4/21/2022 due to an increase in the volatility index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D+ from D- on 4/21/2022 due to an increase in the volatility index.
D
Sell
4/20/2022Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 04/20/2022.
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 04/20/2022.
D
Sell
4/18/2022Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to D from D+ on 4/18/2022 due to a decline in the volatility index.
Alterity Therapeutics Limited (PRNAF) was downgraded to D from D+ on 4/18/2022 due to a decline in the volatility index.
D
Sell
3/31/2022Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D+ from D on 3/31/2022 due to an increase in the volatility index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D+ from D on 3/31/2022 due to an increase in the volatility index.
D
Sell
3/2/2022Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to D from D+ on 3/2/2022 due to a decline in the growth index and valuation index. Total revenue declined 0.75% from $866.3 to $859.8.
Alterity Therapeutics Limited (PRNAF) was downgraded to D from D+ on 3/2/2022 due to a decline in the growth index and valuation index. Total revenue declined 0.75% from $866.3 to $859.8.
D
Sell
2/23/2022Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D+ from D on 2/23/2022 due to an increase in the total return index, volatility index and valuation index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D+ from D on 2/23/2022 due to an increase in the total return index, volatility index and valuation index.
D
Sell
11/23/2021Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index.
D
Sell
11/8/2021Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 11/8/2021 due to a substantial decline in the valuation index and efficiency index. Total capital declined 1.49% from $23.24M to $22.89M.
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 11/8/2021 due to a substantial decline in the valuation index and efficiency index. Total capital declined 1.49% from $23.24M to $22.89M.
D
Sell
4/21/2020Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 4/21/2020 due to a substantial increase in the valuation index and growth index. Operating cash flow increased 0.3% from -$886.4 to -$883.7, and EBIT increased 0.3% from -$1.98M to -$1.98M.
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 4/21/2020 due to a substantial increase in the valuation index and growth index. Operating cash flow increased 0.3% from -$886.4 to -$883.7, and EBIT increased 0.3% from -$1.98M to -$1.98M.
D
Sell
8/14/2019Downgrade
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 8/14/2019 due to a substantial decline in the valuation index.
Alterity Therapeutics Limited (PRNAF) was downgraded to D- from D on 8/14/2019 due to a substantial decline in the valuation index.
D
Sell
7/30/2019Upgraded
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 7/30/2019 due to a substantial increase in the valuation index and volatility index.
Alterity Therapeutics Limited (PRNAF) was upgraded to D from D- on 7/30/2019 due to a substantial increase in the valuation index and volatility index.
D
Sell
10/24/2018Downgrade
Prana Biotechnology Limited (PRNAF) was downgraded to D- from D on 10/24/2018 due to a noticeable decline in the total return index and volatility index.
Prana Biotechnology Limited (PRNAF) was downgraded to D- from D on 10/24/2018 due to a noticeable decline in the total return index and volatility index.
D
Sell
10/8/2018Upgraded
Prana Biotechnology Limited (PRNAF) was upgraded to D from D- on 10/8/2018 due to a large increase in the total return index, volatility index and valuation index.
Prana Biotechnology Limited (PRNAF) was upgraded to D from D- on 10/8/2018 due to a large increase in the total return index, volatility index and valuation index.
D
Sell
8/31/2018Downgrade
Prana Biotechnology Limited (PRNAF) was downgraded to D- from D on 8/31/2018 due to a major decline in the solvency index, efficiency index and volatility index. Total capital declined 3.81% from $12.37M to $11.89M.
Prana Biotechnology Limited (PRNAF) was downgraded to D- from D on 8/31/2018 due to a major decline in the solvency index, efficiency index and volatility index. Total capital declined 3.81% from $12.37M to $11.89M.
D
Sell
3/11/2016Downgrade
Prana Biotechnology Limited (PRNAF) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index.
Prana Biotechnology Limited (PRNAF) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index.
C
Hold
2/29/2016Upgraded
Prana Biotechnology Limited (PRNAF) was upgraded to C- from D+ on 2/29/2016 due to a noticeable increase in the volatility index, growth index and efficiency index. Operating cash flow increased 177.67% from -$956.7 to -$2.66M.
Prana Biotechnology Limited (PRNAF) was upgraded to C- from D+ on 2/29/2016 due to a noticeable increase in the volatility index, growth index and efficiency index. Operating cash flow increased 177.67% from -$956.7 to -$2.66M.
D
Sell
1/15/2016Downgrade
Prana Biotechnology Limited (PRNAF) was downgraded to D+ from C- on 1/15/2016 due to a noticeable decline in the total return index.
Prana Biotechnology Limited (PRNAF) was downgraded to D+ from C- on 1/15/2016 due to a noticeable decline in the total return index.
C
Hold
12/31/2015Upgraded
Prana Biotechnology Limited (PRNAF) was upgraded to C- from D+ on 12/31/2015 due to a noticeable increase in the total return index, efficiency index and valuation index. Total capital increased 0.91% from $29.83M to $30.1M.
Prana Biotechnology Limited (PRNAF) was upgraded to C- from D+ on 12/31/2015 due to a noticeable increase in the total return index, efficiency index and valuation index. Total capital increased 0.91% from $29.83M to $30.1M.
D
Sell
5/6/2015Downgrade
Prana Biotechnology Limited (PRNAF) was downgraded to D+ from C- on 5/6/2015 due to a major decline in the volatility index.
Prana Biotechnology Limited (PRNAF) was downgraded to D+ from C- on 5/6/2015 due to a major decline in the volatility index.
C
Hold
4/21/2015Upgraded
Prana Biotechnology Limited (PRNAF) was upgraded to C- from D+ on 4/21/2015 due to an increase in the valuation index.
Prana Biotechnology Limited (PRNAF) was upgraded to C- from D+ on 4/21/2015 due to an increase in the valuation index.
D
Sell
2/25/2015Upgraded
Prana Biotechnology Limited (PRNAF) was upgraded to D+ from D on 2/25/2015 due to a substantial increase in the volatility index, solvency index and growth index.
Prana Biotechnology Limited (PRNAF) was upgraded to D+ from D on 2/25/2015 due to a substantial increase in the volatility index, solvency index and growth index.
OTC PK
01/21/2025 10:46AM Eastern
Quotes delayed
